UGT1A1 Polymorphism for Irinotecan Dose Escalation in Patients with BRAF-Mutated Metastatic Colorectal Cancer Treated with First-Line Bevacizumab and FOLFIRI

Table 3

Toxicities of 17 patients with mCRC.

Adverse effect	Grades 1–2 (%)	Grade ≥ 3 (%)	Any grade (%)
Anemia	13 (76.5)	0 (0)	13 (76.5)
Fatigue	10 (58.8)	0 (0)	10 (58.8)
Nausea	8 (47.1)	1 (5.9)	9 (52.9)
Neutropenia	8 (47.1)	1 (5.9)	9 (52.9)
Hair loss	8 (47.1)	0 (0)	8 (47.1)
Thrombocytopenia	6 (35.3)	0 (0)	6 (35.3)
Abnormal liver function	6 (35.3)	0 (0)	6 (35.3)
Vomiting	3 (17.6)	1 (5.9)	4 (23.5)
Acute kidney injury	3 (17.6)	0 (0)	3 (17.6)
Diarrhea	2 (11.8)	0 (0)	2 (11.8)
Paresthesia	2 (11.8)	0 (0)	2 (11.8)